Trial intelligence / Profile preview

Phase II trabectedin in advanced retroperitoneal leiomyosarcoma and liposarcoma

2012-005428-14Phase 2Completed

Sponsor: Italian Sarcoma Group
Start: Sep 2013
Modality: Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, open-label, single-arm trial of trabectedin in leiomyosarcoma (LMS), well-differentiated liposarcoma (WDLS) and Liposarcoma, sponsored by Italian Sarcoma Group. Primary endpoint: Growth Modulation Rate responders. Started Sep 2013; status: completed.

Drugs

trabectedin

Conditions

leiomyosarcoma (LMS)well-differentiated liposarcoma (WDLS)Liposarcoma

Beyond the preview

Go deeper on 2012-005428-14.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2012-005428-14.